natgillin/translations-raw huggingface dataset:
Taking this medicine in combination with insulin or medicines that increase insulin release from the pancreas can cause blood sugar levels to drop too low (hypoglycaemia), which may cause symptoms such as shaking, sweating and change in vision, and may affect your ability to drive and use machines. 
Jemanje tega zdravila v kombinaciji z insulinom ali zdravili, ki povečajo izločanje insulina iz trebušne slinavke, lahko povzroči preveliko znižanje krvnega sladkorja (hipoglikemijo), kar lahko povzroči simptome, kot so tresenje, potenje in sprememba vida, ter lahko poslabša sposobnost upravljanja vozil in strojev.
Blood creatinine increased/Glomerular filtration rate decreased and renal-related events Initial increases in mean creatinine and decreases in mean eGFR in patients treated with ertugliflozin were generally transient during continuous treatment. 
Zvišanje kreatinina v krvi/zmanjšanje hitrosti glomerulne filtracije in z ledvicami povezani dogodki Uvodno zvišanje povprečnega kreatinina in zmanjšanje povprečne eGFR pri bolnikih, zdravljenih z ertugliflozinom, je bilo med neprekinjenim zdravljenjem na splošno prehodno.
Alu/PVC/PA/Alu blisters. 
Alu/PVC/PA/Alu pretisni omoti
• Steglatro lowers blood sugar levels in adult patients (aged 18 years and older) with type 2 
• Zdravilo Steglatro znižuje vrednosti krvnega sladkorja pri odraslih bolnikih (starih 18 let ali več) s sladkorno boleznijo tipa 2.
In patients with type 2 diabetes treated with ertugliflozin, clinically meaningful reductions in HbA1c were observed in subgroups defined by age, sex, race, ethnicity, geographic region, baseline BMI, baseline HbA1c, and duration of type 2 diabetes mellitus. 
Pri bolnikih s sladkorno boleznijo tipa 2, zdravljenih z ertugliflozinom, so bila klinično pomembna zmanjšanja HbA1c opažena pri podskupinah, opredeljenih glede na starost, spol, raso, etnično pripadnost, geografsko regijo, indeks telesne mase v izhodišču, HbA1c v izhodišču in trajanje sladkorne bolezni tipa 2.
Dysuria, Blood creatinine increased/Glomerular filtration rate decreased 
disurija, zvišanje kreatinina v krvi/zmanjšanje hitrosti glomerulne filtracije
• if you are allergic to ertugliflozin or any of the other ingredients of this medicine (listed in section 6). 
Ne jemljite zdravila Steglatro • če ste alergični na ertugliflozin ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Ertugliflozin has not been studied in patients with severe hepatic impairment and is not recommended for use in these patients (see section 5.2). 
Ertugliflozina niso preučevali pri bolnikih s hudo okvaro jeter in njegova uporaba pri teh bolnikih ni priporočljiva (glejte poglavje 5.2).
Therefore, Steglatro should not be used during pregnancy. 
Zdravila Steglatro se zato med nosečnostjo ne sme uporabljati.
Packs of 14, 28, 30, 84, 90 and 98 film-coated tablets in non-perforated blisters. 
Pakiranja po 14, 28, 30, 84, 90 in 98 filmsko obloženih tablet v neperforiranih pretisnih omotih.
In the event of an overdose, employ the usual supportive measures (e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute supportive treatment) as dictated by the patient's clinical status. 
V primeru prevelikega odmerjanja ertugliflozina so potrebni običajni podporni ukrepi (npr. odstranitev neabsorbirane vsebine iz prebavil, klinično spremljanje in podporno zdravljenje) glede na bolnikovo klinično stanje.
Steglatro is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: 
Zdravilo Steglatro je indicirano pri odraslih, starih 18 let ali več, s sladkorno boleznijo tipa 2 kot dodatek k dieti in telesni aktivnosti za izboljšanje urejenosti glikemije:
The effect of ertugliflozin on fertility in humans has not been studied. 
Vpliva ertugliflozina na plodnost pri ljudeh niso preučevali.
The recommended starting dose of ertugliflozin is 5 mg once daily. 
Priporočeni začetni odmerek ertugliflozina je 5 mg enkrat na dan.
Ertugliflozin is expected to have diminished efficacy in elderly patients with renal impairment (see sections 4.2 and 4.8). 
Pričakovati je, da ima ertugliflozin pri starejših bolnikih z okvaro ledvic zmanjšano učinkovitost (glejte poglavji 4.2 in 4.8).
Interference with 1,5-anhydroglucitol (1,5-AG) assay Monitoring glycaemic control with 1,5-AG assay is not recommended as measurements of 1,5-AG are unreliable in assessing glycaemic control in patients taking SGLT2 inhibitors. 
Motenje preiskave z 1,5-anhidroglucitolom (1,5-AG) Spremljanje urejenosti glikemije s preiskavo 1,5-AG ni priporočljivo, saj pri bolnikih, ki jemljejo zaviralce SGLT2, z merjenjem 1,5-AG ni mogoče zanesljivo oceniti urejenosti glikemije.
Hypromellose 2910/6 (E464) Lactose monohydrate Macrogol 3350 (E1521) Triacetin (E1518) Titanium dioxide (E171) Iron oxide red (E172) 
Filmska obloga hipromeloza 2910/6 (E464) laktoza monohidrat makrogol 3350 (E1521) triacetin (E1518) titanov dioksid (E171) rdeči železov oksid (E172)
In patients where DKA is suspected or diagnosed, treatment with ertugliflozin should be discontinued immediately. 
Pri bolnikih s sumom na DKA ali z diagnosticirano DKA je treba zdravljenje z ertugliflozinom takoj ukiniti.
Across the clinical program, ketoacidosis was identified in 3 of 3,409 (0.1%) ertugliflozin-treated patients and 0.0% of comparator-treated patients (see section 4.4). 
V kliničnem programu so ketoacidozo ugotovili pri 3 od 3.409 (0,1 %) bolnikov, ki so prejemali ertugliflozin, in pri 0,0 % bolnikov, ki so prejemali primerjalno zdravilo (glejte poglavje 4.4).
General Steglatro should not be used in patients with type 1 diabetes mellitus. 
Splošno Zdravila Steglatro se ne sme uporabljati pri bolnikih s sladkorno boleznijo tipa 1.
Effects of ertugliflozin on the pharmacokinetics of other medicinal products Interaction studies conducted in healthy volunteers suggest that ertugliflozin had no clinically relevant effect on the pharmacokinetics of sitagliptin, metformin, and glimepiride. 
Vpliv ertugliflozina na farmakokinetiko drugih zdravil Študije medsebojnega delovanja, ki so jih izvedli pri zdravih prostovoljcih, kažejo, da ertugliflozin ni imel klinično pomembnega vpliva na farmakokinetiko sitagliptina, metformina ali glimepirida.
The efficacy of ertugliflozin was also assessed separately in a dedicated study of diabetic patients with moderate renal impairment (468 patients with eGFR ≥ 30 to < 60 ml/min/1.73 m 
Učinkovitost ertugliflozina so ocenili ločeno v namenski študiji bolnikov s sladkorno boleznijo z zmerno okvaro ledvic (468 bolnikov z eGFR ≥ 30 do < 60 ml/min/1,73 m
Steglatro is available in Alu/PVC/PA/Alu blisters. 
Tablete zdravila Steglatro so na voljo v Alu/PVC/PA/Alu pretisnih omotih.
EU/1/18/1267/007 (14 film-coated tablets) EU/1/18/1267/008 (28 film-coated tablets) EU/1/18/1267/009 (30 film-coated tablets) EU/1/18/1267/010 (30x1 film-coated tablets) EU/1/18/1267/011 (84 film-coated tablets) EU/1/18/1267/012 (90 film-coated tablets) EU/1/18/1267/014 (98 film-coated tablets) 
EU/1/18/1267/007 (14 filmsko obloženih tablet) EU/1/18/1267/008 (28 filmsko obloženih tablet) EU/1/18/1267/009 (30 filmsko obloženih tablet) EU/1/18/1267/010 (30 x 1 filmsko obložena tableta) EU/1/18/1267/011 (84 filmsko obloženih tablet) EU/1/18/1267/012 (90 filmsko obloženih tablet) EU/1/18/1267/014 (98 filmsko obloženih tablet)
Monitoring of renal function is recommended as follows: - Prior to ertugliflozin initiation and periodically during treatment (see section 4.2). 
Delovanje ledvic je priporočljivo spremljati: - pred uvedbo ertugliflozina in periodično med zdravljenjem (glejte poglavje 4.2).
Balanitis candida and other male genital mycotic infections* 
kandidozni balanitis in druge glivične okužbe moških spolovil*
EU/1/18/1267/001 (14 film-coated tablets) EU/1/18/1267/002 (28 film-coated tablets) EU/1/18/1267/003 (30 film-coated tablets) EU/1/18/1267/004 (30x1 film-coated tablets) EU/1/18/1267/005 (84 film-coated tablets) EU/1/18/1267/006 (90 film-coated tablets) EU/1/18/1267/013 (98 film-coated tablets) 
EU/1/18/1267/001 (14 filmsko obloženih tablet) EU/1/18/1267/002 (28 filmsko obloženih tablet) EU/1/18/1267/003 (30 filmsko obloženih tablet) EU/1/18/1267/004 (30 x 1 filmsko obložena tableta) EU/1/18/1267/005 (84 filmsko obloženih tablet) EU/1/18/1267/006 (90 filmsko obloženih tablet) EU/1/18/1267/013 (98 filmsko obloženih tablet)
What you need to know before you take Steglatro 
Kaj morate vedeti, preden boste vzeli zdravilo Steglatro
Pharmacotherapeutic group: Drugs used in diabetes, Sodium glucose co-transporter 2 (SGLT2) inhibitors, ATC code: A10BK04. 
Farmakoterapevtska skupina: zdravila za zdravljenje sladkorne bolezni, zaviralci natrijevih glukoznih koprenašalcev 2 (SGLT2), oznaka ATC: A10BK04
Steglatro 5 mg film-coated tablets EU/1/18/1267/001 
Steglatro 5 mg filmsko obložene tablete EU/1/18/1267/001
Ertugliflozin works by blocking the SGLT2 protein in your kidneys. 
Ertugliflozin deluje tako, da zavira beljakovino SGLT2 v ledvicah.
Due to its mechanism of action, patients taking Steglatro will test positive for glucose in their urine. 
Zaradi mehanizma delovanja bodo rezultati testov glukoze v urinu pri bolnikih, ki jemljejo zdravilo Steglatro, pozitivni.
In patients tolerating ertugliflozin 5 mg once daily, the dose can be increased to 15 mg once daily if additional glycaemic control is needed. 
Pri bolnikih, ki prenašajo ertugliflozin v odmerku 5 mg enkrat na dan, se odmerek lahko poveča na 15 mg enkrat na dan, če je potrebno dodatno urejanje glikemije.
Steglatro 15 mg film-coated tablets EU/1/18/1267/007 
Steglatro 15 mg filmsko obložene tablete EU/1/18/1267/007
Microcrystalline cellulose (E460) Lactose monohydrate Sodium starch glycolate (Type A) Magnesium stearate (E470b) 
Jedro tablete mikrokristalna celuloza (E460) laktoza monohidrat natrijev karboksimetilškrob (tip A) magnezijev stearat (E470b)
The pack sizes are 14, 28, 30, 84, 90 and 98 filmcoated tablets in non-perforated blisters and 30x1 film-coated tablets in perforated unit dose blisters. 
Velikosti pakiranj so po 14, 28, 30, 84, 90 in 98 filmsko obloženih tablet v neperforiranih pretisnih omotih in 30 x 1 filmsko obložena tableta v perforiranih pretisnih omotih za enkratni odmerek.
Pool of placebo-controlled trials evaluating Steglatro 5 mg and 15 mg The primary assessment of safety was conducted in a pool of three 26-week, placebo-controlled trials. 
Združena s placebom nadzorovana preskušanja za oceno 5 mg in 15 mg zdravila Steglatro Prvotno oceno varnosti so izvedli v treh združenih 26-tedenskih, s placebom nadzorovanih preskušanjih.
What Steglatro looks like and contents of the pack 
Izgled zdravila Steglatro in vsebina pakiranja
¶, Haemoglobin increased 
¶, zvišanje hemoglobina zvišanje BUN
In patients with volume depletion, correcting this condition prior to initiation of ertugliflozin is recommended (see section 4.4). 
Pri bolnikih s hipovolemijo je priporočljivo to stanje odpraviti pred uvedbo ertugliflozina (glejte poglavje 4.4).
Pharmacologically-mediated effects were observed in juvenile rats (see section 5.3). 
Pri mladih podganah so opažali farmakološko posredovane učinke (glejte poglavje 5.3).
If you stop taking Steglatro 
Če ste prenehali jemati zdravilo Steglatro
Removal of ertugliflozin by haemodialysis has not been studied. 
Odstranjevanja ertugliflozina s hemodializo niso preučili.
Coadministration of simvastatin with ertugliflozin resulted in a 24% and 19% increase in AUC and Cmax of simvastatin, respectively, and 30% and 16% increase in AUC and Cmax of simvastatin acid, respectively. 
Sočasna uporaba simvastatina in ertugliflozina je povzročila povečanje AUC simvastatina za 24 % in njegove Cmax za 19 % ter povečanje AUC simvastatina v obliki kisline za 30 % in njegove Cmax za 16 %.
Steglatro is a member of a group of medicines called sodium glucose co-transporter-2 (SGLT2) inhibitors. 
Zdravilo Steglatro spada v skupino zdravil, imenovanih zaviralci natrijevih glukoznih koprenašalcev 2 (SGLT2).
What Steglatro is and what it is used for 
Kaj je zdravilo Steglatro in za kaj ga uporabljamo
Excipient(s) with known effect Each tablet contains 28 mg of lactose (as monohydrate). 
Pomožna(e) snov(i) z znanim učinkom Ena tableta vsebuje 28 mg laktoze (v obliki monohidrata).
Therefore, symptomatic hypotension may occur after initiating Steglatro (see section 4.8), particularly in patients with impaired renal function (eGFR less than 60 ml/min/1.73 m2 or CrCl less than 
Po uvedbi zdravila Steglatro se zato lahko pojavi simptomatska hipotenzija (glejte poglavje 4.8), zlasti pri bolnikih z okvarjenim delovanjem ledvic (eGFR manj kot 60 ml/min/1,73 m ali CrCl manj kot
Warnings and precautions Talk to your doctor, pharmacist, or nurse before and while taking Steglatro if you: 
Opozorila in previdnostni ukrepi Pred začetkom jemanja zdravila Steglatro in med njegovim jemanjem se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro:
What Steglatro is Steglatro contains the active substance ertugliflozin. 
Kaj je zdravilo Steglatro Zdravilo Steglatro vsebuje učinkovino ertugliflozin.
If you forget to take Steglatro 
Če ste pozabili vzeti zdravilo Steglatro
This medicine has no or negligible influence on the ability to drive and use machines. 
Vpliv na sposobnost upravljanja vozil in strojev To zdravilo nima ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
The placebo-corrected reductions of ertugliflozin 5 or 15 mg in combination with sitagliptin were 2.16 and 2.56 mmol/l. 
Za placebo korigirano znižanje z ertugliflozinom v odmerku 5 mg ali 15 mg v kombinaciji s sitagliptinom je bilo 2,16 oz. 2,56 mmol/l.
Steglatro should not be used during breast-feeding. 
Zdravila Steglatro se med dojenjem ne sme uporabljati.
Excipient(s) with known effect Each tablet contains 85 mg of lactose (as monohydrate). 
Pomožna(e) snov(i) z znanim učinkom Ena tableta vsebuje 85 mg laktoze (v obliki monohidrata).
Active-controlled study of ertugliflozin versus glimepiride as add-on combination therapy with metformin 
Faktorska študija z ertugliflozinom in sitagliptinom kot dodatkom h kombiniranemu zdravljenju z metforminom
In a subsequent analysis excluding those subjects who used the prohibited medication, ertugliflozin 5 mg and 15 mg were associated with placebo-corrected reductions in HbA1c of -0.14 (-0.36, 0.08) and -0.33 (-0.55, -0.11) 
V naslednji analizi, ki je izključevala osebe, ki so uporabljale prepovedana zdravila, je bilo s placebom korigirano znižanje HbA1c, povezano z ertugliflozinom 5 mg, -0,14 (-0,36; 0,08), in z ertugliflozinom 15 mg -0,33 (-0,55; -0,11).
Before initiating ertugliflozin, factors in the patient history that may predispose to ketoacidosis should be considered. 
Pred uvedbo ertugliflozina je treba glede na bolnikovo anamnezo upoštevati dejavnike, ki bi lahko povečali nagnjenost h ketoacidozi.
Difference from glimepiride (LS mean 
Razlika v primerjavi z glimepiridom (povprečje LS
In the pre- and postnatal development study, decreased postnatal growth and development were observed in rats administered ertugliflozin gestation day 6 through lactation day 21 at ≥ 100 mg/kg/day (estimated 239 times the human exposure at the maximum clinical dose of 15 mg/day, based on AUC). 
V študiji prenatalnega in postnatalnega razvoja so ugotovili zmanjšano postnatalno rast in razvoj pri podganah, ki so dobivale ertugliflozin od 6. dne gestacije do 21. dne dojenja v odmerku ≥ 100 mg/kg/dan (ocenjeni 239-kratnik izpostavljenosti pri človeku med uporabo največjega kliničnega odmerka 15 mg/dan na podlagi AUC).
Following single-dose oral administration of 5 mg and 15 mg of ertugliflozin, peak plasma concentrations (median Tmax) of ertugliflozin occur at 1 hour postdose under fasted conditions. 
Po enkratnem peroralnem odmerku 5 mg ali 15 mg ertugliflozina na tešče se največja koncentracija ertugliflozina v plazmi (mediani tmax) pojavi 1 uro po odmerku.
In a Phase 1 clinical pharmacology study in patients with type 2 diabetes and mild, moderate, or severe renal impairment (as determined by eGFR), following a single-dose administration of 15 mg ertugliflozin, the mean increases in AUC of ertugliflozin were ≤ 1.7-fold, compared to subjects with normal renal function. 
V klinični farmakološki študiji 1. faze so pri bolnikih s sladkorno boleznijo tipa 2 in blago, zmerno ali hudo okvaro ledvic (določeno glede na eGFR) v primerjavi z osebami z normalnim delovanjem ledvic po uporabi enkratnega odmerka 15 mg ertugliflozina ugotovili povprečno ≤ 1,7-kratno povečanje AUC ertugliflozina.
When ertugliflozin was administered to juvenile rats from postnatal day (PND) 21 to PND 90, a period of renal development corresponding to the late second and third trimesters of human pregnancy, increased kidney weights, dilatation of the renal pelvis and tubules, and renal tubular mineralization were seen at an exposure 13 times the maximum clinical dose of 15 mg/day, based on AUC. 
V primeru uporabe ertugliflozina pri podganjih mladičih od 21. do 90. postnatalnega dne (to obdobje razvoja ledvic ustreza poznemu drugemu in tretjemu mesecu nosečnosti pri človeku) so ugotovili večjo maso ledvic, razširitev ledvičnega meha in tubulov in mineralizacijo ledvičnih tubulov pri izpostavljenostih, ki so bile na podlagi AUC 13-kratnik največjega kliničnega odmerka 15 mg/dan.
Least squares means adjusted for treatment, time, prior antihyperglycaemic medication. 
Povprečja po metodi najmanjših kvadratov, prilagojena za zdravljenje, čas, predhodno antihiperglikemično zdravljenje
Patients [N (%)] with HbA1c < 7% 
Bolniki [n (%)] s HbA1c < 7 %
Hypoglycaemia with concomitant use with insulin and insulin secretagogues Ertugliflozin may increase the risk of hypoglycaemia when used in combination with insulin and/or an insulin secretagogue, which are known to cause hypoglycaemia (see section 4.8). 
Hipoglikemija med sočasno uporabo z insulinom in insulinskimi sekretagogi Ertugliflozin lahko poveča tveganje za hipoglikemijo, če se uporablja v kombinaciji z insulinom in/ali insulinskim sekretagogom, za katera je znano, da povzročata hipoglikemijo (glejte poglavje 4.8).
Steglatro contains lactose 
Zdravilo Steglatro vsebuje laktozo
Only 1.5% of the administered dose was excreted as unchanged ertugliflozin in urine and 34% as unchanged ertugliflozin in faeces, which is likely due to biliary excretion of glucuronide metabolites and subsequent hydrolysis to parent. 
1,5 % uporabljenega odmerka, v blatu pa 34 % uporabljenega odmerka, kar je verjetno posledica izločanja glukuronidnih presnovkov v žolču in poznejše hidrolize teh v matično spojino.
Talk with your doctor about the best way to feed your baby if you take Steglatro. 
Če jemljete zdravilo Steglatro, se z zdravnikom posvetujte o najboljšem načinu za hranjenje dojenčka.
†, 95% CI) * N includes all patients who received at least one dose of study medication and had at least one measurement of the outcome variable. 
†, 95 % IZ) * n vključuje vse bolnike, ki so prejeli vsaj en odmerek študijskega zdravila in so imeli vsaj eno meritev spremenljivke izida.
Table 4: Results at Week 52 from an active-controlled study comparing Steglatro to glimepiride as add-on therapy in patients inadequately controlled on metformin* 
Preglednica 4: Rezultati s primerjalno učinkovino nadzorovane študije primerjave zdravila Steglatro in glimepirida kot dodatka zdravljenju bolnikov, neustrezno urejenih z metforminom, po 52 tednih*
- More frequently in patients with an eGFR below 60 ml/min/1.73 m2 or a CrCl below 60 ml/min. 
- pogosteje pri bolnikih z eGFR pod 60 ml/min/1,73 m ali CrCl pod 60 ml/min.
Steglatro should be discontinued when eGFR is persistently less than 45 ml/min/1.73 m 2 or CrCl is persistently less than 45 ml/min. 
Zdravilo Steglatro je treba ukiniti, kadar je eGFR neprestano manj kot 45 ml/min/1,73 m ali CrCl neprestano manj kot 45 ml/min.
The risk of diabetic ketoacidosis must be considered in the event of non-specific symptoms such as nausea, vomiting, anorexia, abdominal pain, excessive thirst, difficulty breathing, confusion, unusual fatigue or sleepiness. 
Če se pojavijo nespecifični simptomi, kot so navzea, bruhanje, anoreksija, bolečine v trebuhu, prekomerna žeja, težave z dihanjem, zmedenost, neobičajna utrujenost ali zaspanost, je treba upoštevati tveganje za diabetično ketoacidozo.
No dose adjustment of ertugliflozin is recommended based on age. 
Prilagoditev odmerka ertugliflozina glede na starost ni potrebna.
In the study of patients inadequately controlled on metformin with baseline HbA1c from 7.5-11.0%, among the subgroup of patients with a baseline HbA1c ≥ 10%, the combination of ertugliflozin 5 mg or 15 mg with sitagliptin resulted in reductions of HbA1c of 2.35% and 2.66% compared to 2.10%, 1.30%, and 1.82% for ertugliflozin 5 mg, ertugliflozin 15 mg and sitagliptin alone, respectively. 
V študiji pri bolnikih z nezadostno nadzorovano hiperglikemijo ob zdravljenju z metforminom z izhodiščnim HbA1c od 7,5 do 11,0 %, je med podskupino bolnikov z izhodiščnim HbA1c ≥ 10 % kombinacija ertugliflozina 5 mg oz. 15 mg s sitagliptinom zmanjšala HbA1c za 2,35 % oz. 2,66 % v primerjavi z 2,10 %, 1,30 % oz. 1,82 % za ertugliflozin 5 mg, ertugliflozin 15 mg oz. sitagliptin uporabljenih samostojno.
The combination of ertugliflozin and sitagliptin resulted in significantly greater reductions in FPG compared to sitagliptin or ertugliflozin alone or placebo. 
Kombinacija ertugliflozina in sitagliptina je znižala glukozo v plazmi na tešče značilno bolj kot sitagliptin ali ertugliflozin vsak sam ali kot placebo.
Moderate renal impairment 
Zmerna okvara ledvic
Mean percent changes from baseline for ertugliflozin 5 mg and 15 mg versus placebo, respectively, were LDL-C 5.8% and 8.4% versus 3.2%; total cholesterol 2.8% and 5.7% versus 1.1%; however, HDL-C 6.2% and 7.6% versus 1.9%. 
Povprečne spremembe v odstotkih od izhodišča za 5 mg in 15 mg ertugliflozina v primerjavi s placebom so znašale: za LDL-C 5,8 % oz. 8,4 % za ertugliflozin in 3,2 % za placebo, za celokupni holesterol 2,8 % oz. 5,7 % za ertugliflozin in 1,1 % za placebo; za HDL-C pa 6,2 % oz. 7,6 % za ertugliflozin in 1,9 % za placebo.
No effects on fertility were observed at 250 mg/kg/day (approximately 386 times human unbound exposure at the MRHD of 15 mg/day based on AUC 
Pri odmerku 250 mg/kg/dan niso opažali vplivov na plodnost (gre za približno 386-kratnik izpostavljenosti nevezanemu zdravilu pri človeku ob MRHD 15 mg/dan na podlagi primerjave AUC).
Patients [N (%)] with HbA1c < 7% 66 (26.4) Body Weight (kg) 
Bolniki [n (%)] s HbA1c < 7 % 66 (26,4)
Patients with type 2 diabetes inadequately controlled on metformin monotherapy (≥ 1,500 mg/day) were randomised to one of five active-treatment arms: ertugliflozin 5 mg or 15 mg, sitagliptin 100 mg, or sitagliptin 100 mg in combination with 5 mg or 15 mg ertugliflozin administered once daily in addition to continuation of background metformin therapy (see Table 5). 
Bolnike s sladkorno boleznijo tipa 2 in neustrezno urejene s samostojnim zdravljenjem z metforminom (≥ 1.500 mg/dan) so randomizirali v eno od petih skupin z aktivnim zdravljenjem: ertugliflozin 5 mg ali 15 mg, sitagliptin 100 mg ali sitagliptin 100 mg v kombinaciji s 5 mg ali 15 mg ertugliflozina enkrat na dan ob hkratnem nadaljevanju osnovnega zdravljenja z metforminom (glejte preglednico 5).
Table 5: Results at Week 26 from a factorial study with Steglatro and sitagliptin as add-on combination therapy with metformin compared to individual components alone* 
Preglednica 5: Rezultati faktorske študije z zdravilom Steglatro in sitagliptinom kot dodatkom h kombiniranemu zdravljenju z metforminom v primerjavi s posameznimi komponentami po 26 tednih*
Patients [N (%)] with HbA1c <7% Body Weight (kg) 
Bolniki [n (%)] s HbA1c < 7 % Telesna masa (kg)
The combination of ertugliflozin 5 or 15 mg and sitagliptin resulted in incremental FPG reductions of 0.46 to 0.65 mmol/l compared to the ertugliflozin alone or 1.02 to 1.28 mmol/l compared to sitagliptin alone. 
Kombinacija ertugliflozina v odmerku 5 mg ali 15 mg in sitagliptina je dodatno znižala glukozo v plazmi na tešče za 0,46 oz. 0,65 mmol/l v primerjavi s samim ertugliflozinom in za 1,02 oz. 1,28 mmol/l v primerjavi s samim sitagliptinom.